Clinical Trial

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-13
Trial Details
NCT Number NCT07587021
Lead Sponsor YolTech Therapeutics Co., Ltd
Conditions Primary Hyperoxaluria Type 1, PH1
Enrollment 36 participants
Start Date 2026-08
Primary Completion 2027-08 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-12